MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Zhao, Yuanyin ^a   Li, Yuping ^a   Lou, Guiyu ^a   Zhao, Li ^a   Xu, Zhizhen ^a   Zhang, Yan ^a   He, Fengtian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 137; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CCNE1 GENE; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ERRALPHA GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REPORTER GENE; WNT11 GENE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84862489809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039102     Document Type: Article

References (58)

1. Stingl J, Caldas C, (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791-799.
2. Ali S, Coombes RC, (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112.
3. Law ML, Kao FT, Wei Q, Hartz JA, Greene GL, et al. (1987) The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc Natl Acad Sci U S A 84: 2877-2881.
4. Jahanzeb M, (2008) Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 8: 324-333.
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
8. Jarzabek K, Koda M, Kozlowski L, Sulkowski S, Kottler ML, et al. (2009) The significance of the expression of ERRalpha as a potential biomarker in breast cancer. J Steroid Biochem Mol Biol 113: 127-133.
9. Giguere V, Yang N, Segui P, Evans RM, (1988) Identification of a new class of steroid hormone receptors. Nature 331: 91-94.
10. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, et al. (2002) Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 9: 303-313.
11. Kallen J, Schlaeppi JM, Bitsch F, Filipuzzi I, Schilb A, et al. (2004) Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. J Biol Chem 279: 49330-49337.
12. Giguere V, (2008) Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29: 677-696.
13. Ariazi EA, Clark GM, Mertz JE, (2002) Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62: 6510-6518.
14. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, et al. (2004) Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res 64: 4670-4676.
15. Yang C, Zhou D, Chen S, (1998) Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res 58: 5695-5700.
16. Seely J, Amigh KS, Suzuki T, Mayhew B, Sasano H, et al. (2005) Transcriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) by estrogen-related receptor alpha. Endocrinology 146: 3605-3613.
17. Deblois G, Hall JA, Perry MC, Laganiere J, Ghahremani M, et al. (2009) Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res 69: 6149-6157.
18. Stein RA, Chang CY, Kazmin DA, Way J, Schroeder T, et al. (2008) Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 68: 8805-8812.
19. Barry JB, Giguere V, (2005) Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha. Cancer Res 65: 6120-6129.
20. Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE, (2007) Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Mol Cancer Res 5: 71-85.
21. Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, et al. (2010) Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res 70: 10277-10287.
22. Yang C, Chen S, (1999) Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res 59: 4519-4524.
23. Busch BB, Stevens WC Jr, Martin R, Ordentlich P, Zhou S, et al. (2004) Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. J Med Chem 47: 5593-5596.
24. Chisamore MJ, Cunningham ME, Flores O, Wilkinson HA, Chen JD, (2009) Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells. PLoS One 4: e5624.
25. Laganiere J, Tremblay GB, Dufour CR, Giroux S, Rousseau F, et al. (2004) A polymorphic autoregulatory hormone response element in the human estrogen-related receptor alpha (ERRalpha) promoter dictates peroxisome proliferator-activated receptor gamma coactivator-1alpha control of ERRalpha expression. J Biol Chem 279: 18504-18510.
26. Liu D, Zhang Z, Teng CT, (2005) Estrogen-related receptor-gamma and peroxisome proliferator-activated receptor-gamma coactivator-1alpha regulate estrogen-related receptor-alpha gene expression via a conserved multi-hormone response element. J Mol Endocrinol 34: 473-487.
27. Liu D, Zhang Z, Gladwell W, Teng CT, (2003) Estrogen stimulates estrogen-related receptor alpha gene expression through conserved hormone response elements. Endocrinology 144: 4894-4904.
28. Lai EC, (2002) Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364.
29. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
30. Friedman RC, Farh KK, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
31. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
32. Wu W, Sun M, Zou GM, Chen J, (2007) MicroRNA and cancer: Current status and prospective. Int J Cancer 120: 953-960.
33. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
34. Le Quesne J, Caldas C, (2010) Micro-RNAs and breast cancer. Mol Oncol 4: 230-241.
35. O'Day E, Lal A, (2011) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201-210.
36. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
37. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
38. Enright AJ, John B, Gaul U, Tuschl T, Sander C, et al. (2003) MicroRNA targets in Drosophila. Genome Biol 5: R1.
39. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, et al. (2011) The metabolic regulator ERRalpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 20: 500-510.
40. Chisamore MJ, Wilkinson HA, Flores O, Chen JD, (2009) Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts. Mol Cancer Ther 8: 672-681.
41. Bianco S, Lanvin O, Tribollet V, Macari C, North S, et al. (2009) Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. J Biol Chem 284: 23286-23292.
42. Bianco S, Sailland J, Vanacker JM, (2012) ERRs and cancers: Effects on metabolism and on proliferation and migration capacities. J Steroid Biochem Mol Biol 130: 180-185.
43. Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, et al. (2010) WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 70: 9298-9308.
44. Deblois G, Giguere V, (2011) Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. Biochim Biophys Acta 1812: 1032-1040.
45. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, et al. (2010) Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 70: 6609-6618.
46. Chen Q, Chen X, Zhang M, Fan Q, Luo S, et al. (2011) miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 56: 2009-2016.
47. Chen X, Wang J, Shen H, Lu J, Li C, et al. (2011) Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci 52: 1193-1199.
48. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J, (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68: 2094-2105.
49. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14.
50. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, et al. (2010) MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis 31: 864-870.
51. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, Laframboise WA, et al. (2011) MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 117: 1454-1462.
52. Liu M, Lang N, Qiu M, Xu F, Li Q, et al. (2011) miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int J Cancer 128: 1269-1279.
53. Bieche I, Tozlu S, Girault I, Lidereau R, (2004) Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Mol Cancer 3: 37-46.
54. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, et al. (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12: 3319-3328.
55. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ, (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23: 1029-1039.
56. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, et al. (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108: 3761-3766.
57. Kirikoshi H, Sekihara H, Katoh M, (2001) Molecular cloning and characterization of human WNT11. Int J Mol Med 8: 651-656.
58. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, et al. (2010) Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 9: 55-65.